A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With Relapsed / Refractory Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2018
At a glance
- Drugs AMG-562 (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 12 Nov 2018 Planned End Date changed from 4 Nov 2020 to 4 May 2021.
- 12 Nov 2018 Planned primary completion date changed from 4 Nov 2020 to 4 May 2021.
- 12 Nov 2018 Status changed from not yet recruiting to recruiting.